EMEA-003502-PIP01-23
Submitted by Anonymous (not verified) on 9 July 2025 - 17:14
EMEA-003502-PIP01-23
EMEA-003622-PIP01-24
Submitted by Anonymous (not verified) on 9 July 2025 - 17:07
EMEA-003622-PIP01-24
EMEA-003344-PIP01-22-M01
Submitted by Anonymous (not verified) on 9 July 2025 - 17:00
EMEA-003344-PIP01-22-M01
EMEA-003253-PIP01-22-M01
Submitted by Anonymous (not verified) on 9 July 2025 - 17:00
EMEA-003253-PIP01-22-M01
Guide to CTIS training material catalogue
Submitted by Anonymous (not verified) on 9 July 2025 - 16:58
Guide to CTIS training material catalogue
EMEA-003607-PIP01-24
Submitted by Anonymous (not verified) on 9 July 2025 - 16:57
EMEA-003607-PIP01-24
Orphan designation: tasimelteon Treatment of non-24-hour sleep-wake disorders in blind people with no light perception, 23/02/2011 Expired
Submitted by Anonymous (not verified) on 9 July 2025 - 15:56
Orphan designation: tasimelteon Treatment of non-24-hour sleep-wake disorders in blind people with no light perception, 23/02/2011 Expired
Human medicines European public assessment report (EPAR): Hetlioz, tasimelteon, Date of authorisation: 03/07/2015, Revision: 9, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2025 - 15:55
Human medicines European public assessment report (EPAR): Hetlioz, tasimelteon, Date of authorisation: 03/07/2015, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Toujeo (previously Optisulin), insulin glargine, Date of authorisation: 26/06/2000, Revision: 37, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2025 - 15:45
Human medicines European public assessment report (EPAR): Toujeo (previously Optisulin), insulin glargine, Date of authorisation: 26/06/2000, Revision: 37, Status: Authorised
Clinical Trial Information System (CTIS) structured data form - Notifications, Annual Safety Report (ASR) and results
Submitted by Anonymous (not verified) on 9 July 2025 - 15:41
Clinical Trial Information System (CTIS) structured data form - Notifications, Annual Safety Report (ASR) and results